Summary

Pomerantz Law Firm Announces the Filing of a Class Action Against Medical Properties Trust, Inc. and Certain Officers – MPW

Retrieved on: 
Monday, November 13, 2023
Ext, Prospect, NYSE, LLP, Action Replay, Investment, Hospital, Complaint, MPW, WSJ, District court, The Wall Street Journal, DMHC, Person, Summary, Medical Properties Trust, Court, Prior, Health, Pomerantz, Cryptocurrency, Archery

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Medical Properties Trust, Inc. (“MPW” or the “Company”) (NYSE: MPW) and certain officers.

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Medical Properties Trust, Inc. (“MPW” or the “Company”) (NYSE: MPW) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • MPW is a self-advised real estate investment trust that was formed to acquire and develop net-leased healthcare facilities.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Medical Properties Trust, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 28, 2023 – (NYSE: MPW)

Retrieved on: 
Monday, November 13, 2023
Fraud, MPW, Summary, NEXT, Medical Properties Trust, Health, Holding company, Security (finance)

Appointment as lead plaintiff is not required to partake in any recovery.

Key Points: 
  • Appointment as lead plaintiff is not required to partake in any recovery.
  • DEADLINE: November 28, 2023 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is November 28, 2023.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Medical Properties Trust, Inc. (MPW)

Retrieved on: 
Friday, November 10, 2023
Defendant, Suite, NYSE, Investment, GPM, MPW, WSJ, The Wall Street Journal, DMHC, Summary, Medical Properties Trust, Court, News, Health, Pharmaceutical industry, Prospect

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, MPW’s stock price fell $0.57, or 7.6%, to close at $6.93 per share on August 18, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

MEDICAL PROPERTIES TRUST INC. STOCK ALERT: Don't Miss the Lead Plaintiff Deadline in the MPW Class Action, Contact Robbins LLP Today

Retrieved on: 
Thursday, November 9, 2023
Prospect, NYSE, SAN, LLP, Complaint, MPW, DMHC, Person, Summary, Medical Properties Trust, Health, Security (finance), Inc.

MPW is a self-advised real estate investment trust (“REIT”) that was formed to acquire and develop net-leased healthcare facilities.

Key Points: 
  • MPW is a self-advised real estate investment trust (“REIT”) that was formed to acquire and develop net-leased healthcare facilities.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What is this Case About: Medical Properties Trust, Inc. (MPW) Misled Investors Regarding its Recapitalization Transaction with Prospect Medical Holdings, Inc.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Medical Properties Trust, Inc. (MPW) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Thursday, November 9, 2023
NYSE, Telephone, LLP, CASE, MPW, CLASS, Summary, NEXT, Medical Properties Trust, Court, Health, COST

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Medical Properties Trust, Inc. ("MPW" or the "Company") (NYSE: MPW) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Medical Properties Trust, Inc. ("MPW" or the "Company") (NYSE: MPW) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MPW investors who were adversely affected by alleged securities fraud between May 23, 2023 and August 17, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    MPW investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

MPW INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MPW To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, November 9, 2023
Disclosure, NYSE, PHP, Advertising, LLP, Investment, Woman, MPW, WSJ, The Wall Street Journal, DMHC, California Public Records Act, Summary, Medical Properties Trust, Hospital, Court, Health, Security (finance), Cryptocurrency, Prospect

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Medical Properties Trust, Inc. (“MPW” or the “Company”) (NYSE: MPW) and reminds investors of the November 28, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • MPW is a self-advised real estate investment trust that was formed to acquire and develop net-leased healthcare facilities.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding MPW’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Medical Properties Trust, Inc. (MPW)

Retrieved on: 
Monday, November 27, 2023
Class Action Lawsuit, Professional Services, Legal, Defendant, Suite, NYSE, Law, MPW, WSJ, The Wall Street Journal, DMHC, Summary, Medical Properties Trust, Court, News, Health, Security (finance), Sales, Prospect

If you are a shareholder who suffered a loss, click here to participate.

Key Points: 
  • If you are a shareholder who suffered a loss, click here to participate.
  • On this news, MPW’s stock price fell $0.57, or 7.6%, to close at $6.93 per share on August 18, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

MPT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Medical Properties Trust, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 25, 2023
Class Action Lawsuit, Professional Services, Legal, Prospect, NYSE, Telephone, MPT, Complaint, MPW, Jeanne Eagels, District court, DMHC, Person, P.C, Summary, Medical Properties Trust, Court, News, Health, Security (finance)

Investors have until November 28, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 28, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • According to the complaint, on May 23, 2023, MPW issued a press release announcing that it had entered into a recapitalization transaction (the “Recap Transaction”) with Prospect Medical Holdings, Inc. (“Prospect”), a health care management services organization.
  • On this news, MPW's stock price fell $0.57 per share, or 7.6%, to close at $6.93 per share on August 18, 2023.

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

Retrieved on: 
Tuesday, November 14, 2023
Mental Health, Medical Supplies, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Oncology, Research, Annual general meeting, NCCN, ART, Lymph node, National Comprehensive Cancer Network, Risk, ASDS, Patient, BWH, SLN, SCC, Abstract, MPH, Diagnosis, University, Medicare, Society, Summary, GEP, Metastasis, T2A, Pharmaceutical industry, Medical imaging, Brigham

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.
  • “The robust data presented at ASDS underscores the value of GEP testing across multiple skin cancer indications” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences.
  • Summary: ART is recommended based on high-risk clinicopathologic features of SCC, but these criteria are wide-ranging, encompassing a broad range of patients.
  • Additionally, a DecisionDx-SCC Class 2B result was the only risk factor that successfully identified patients who would benefit from ART.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Retrieved on: 
Friday, December 1, 2023
BRCA1, HR, PALB2, Magnetic resonance imaging, Nottingham Prognostic Index, Woman, Research, Prevalence, Gene, ICI, Breast cancer, Cancer, DS, Risk, Disease, Epistasis, Patient, Tumor microenvironment, DCIS, Exact sciences, Ductal carcinoma, Gene expression, Genetic testing, Messenger, BRCA2, NPI, HER2, MammaPrint, Oncotype (Denmark), Medicine, Biomarker, ERBB2, Summary, Neoplasm, Recurrence, Clinical, TNBC, Medical imaging, Birth control, Vaccine, MD

"Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.

Key Points: 
  • "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients.
  • In cooperation with several leading breast cancer research organizations, Exact Sciences will present late-breaking data and a study included in the SABCS press program.
  • Results from Puerto Rico will also detail germline findings for a cohort of women, most of whom had a personal or familial history of breast cancer.
  • Exact Sciences will also host a discussion about the Oncotype DX Breast Recurrence Score test and the RSClin® Tool.